University of California San Francisco

Publications

  1. Characterization of small intestinal neuroendocrine tumorlets.
    2026 | PubMed
  2. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC).
    2024 | PubMed
  3. ASO Author Reflections: Minimally Invasive Surgery for Prototypical Small Intestinal Neuroendocrine Tumors.
    2024 | PubMed
  4. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    2023 | PubMed
  5. Contemporary Trends in Malignant Peritoneal Mesothelioma: Incidence and Survival in the United States.
    2022 | PubMed
  6. Evidence-Based Guidelines for Branch-Duct Intraductal Papillary Mucinous Neoplasm Management: Still a Lot of Room to Grow.
    2021 | PubMed
  7. Randomized Clinical Trial of Nasogastric Tube Placement After Pancreaticoduodenectomy.
    2020 | PubMed
  8. Adjuvant Therapy for Ampullary Cancer.
    2019 | PubMed
  9. Progress in the March to Precision Cancer Medicine: Left, Right, Left.
    2018 | PubMed
  10. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    2015 | PubMed
  11. Home, sweet home, after surgery.
    2014 | PubMed
  12. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    2011 | PubMed
  13. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    2008 | PubMed
  14. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    2007 | PubMed
  15. A non-lymphocyte-depleting monoclonal antibody to the adhesion molecule LFA-1 (CD11a) prevents sensitization to alloantigens and effectively prolongs the survival of heart allografts.
    1993 | PubMed
  16. 4D-MRI at 0.55T for internal target volume delineation in liver radiation therapy planning.
    2025 | PubMed
  17. Burdens of Gastroenteropancreatic Neuroendocrine Neoplasm by Diverse Race and Ethnicities- A Rigorous Structural Equation Modeling.
    2025 | PubMed
  18. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
    2024 | PubMed
  19. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.
    2023 | PubMed
  20. Preclinical Models of Neuroendocrine Neoplasia.
    2022 | PubMed
  21. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    2021 | PubMed
  22. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms.
    2021 | PubMed
  23. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
    2020 | PubMed
  24. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  25. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    2019 | PubMed
  26. Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.
    2018 | PubMed
  27. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
    2017 | PubMed
  28. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    2016 | PubMed
  29. Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?
    2015 | PubMed
  30. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
    2014 | PubMed
  31. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  32. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  33. Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
    2008 | PubMed
  34. Targeting growth factors and angiogenesis; using small molecules in malignancy.
    2006 | PubMed
  35. Vascular endothelial growth factor as a therapeutic target in cancer.
    2004 | PubMed
  36. Shedding old paradigms: developing viruses to treat cancer.
    2002 | PubMed
  37. RBMS1 Suppresses Colon Cancer Metastasis through Targeted Stabilization of Its mRNA Regulon.
    2020 | PubMed
  38. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  39. RasGRP1 opposes proliferative EGFR-SOS1-Ras signals and restricts intestinal epithelial cell growth.
    2015 | PubMed
  40. Imaging a functional tumorigenic biomarker in the transformed epithelium.
    2012 | PubMed
  41. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  42. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    2008 | PubMed
  43. [Liver metastases from colorectal cancer. Is the practice of surgery based on the best clinical evidence possible?].
    2005 | PubMed
  44. Distinguishing features of self-limiting adult small-bowel intussusception identified at CT.
    2003 | PubMed
  45. A double-blind controlled therapeutic trial of lorazepam vs medazepam in psychosomatic conditions in general practice.
    1975 | PubMed
  46. Phase II trial with nivolumab and sorafenib in HCC identified enrichment of immunosuppressive monocytes in patients with Child-Pugh B liver dysfunction.
    2026 | PubMed
  47. Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma.
    2026 | PubMed
  48. Characterization of tumor-associated microbiome in multifocal small intestinal neuroendocrine tumors (SI-NETs).
    2025 | PubMed
  49. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma.
    2024 | PubMed
  50. Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors.
    2024 | PubMed
  51. National Practice Patterns in Malignant Peritoneal Mesothelioma: Updates in Management and Survival.
    2023 | PubMed
  52. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors.
    2022 | PubMed
  53. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  54. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors.
    2020 | PubMed
  55. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stratification Be Favorable Toward Standardization?
    2019 | PubMed
  56. Gastrocutaneous Fistula in a Patient with Locally Recurrent MSI-High Colorectal Cancer: Local Complications Arising from Therapeutic Response to Immune Checkpoint Blockade.
    2017 | PubMed
  57. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer.
    2014 | PubMed
  58. Reply to P.H. Sugarbaker.
    2013 | PubMed
  59. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  60. Immunostaining for peroxisome proliferator gamma distinguishes dedifferentiated liposarcoma from other retroperitoneal sarcomas.
    2008 | PubMed
  61. Notch signaling induces rapid degradation of achaete-scute homolog 1.
    2002 | PubMed
  62. Characterization of small intestinal neuroendocrine tumorlets.
    2026 | PubMed
  63. Consensus Guideline for the Management of Peritoneal Metastases from Neuroendocrine Neoplasms.
    2025 | PubMed
  64. Updated Survival Follow-Up for Phase Ib Trial of the Histone Deacetylase Inhibitor Abexinostat With Pazopanib in Patients With Solid Tumor Malignancies.
    2024 | PubMed
  65. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
    2023 | PubMed
  66. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
    2023 | PubMed
  67. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
    2022 | PubMed
  68. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    2021 | PubMed
  69. Carcinoid Crisis-Induced Acute Systolic Heart Failure.
    2020 | PubMed
  70. Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.
    2020 | PubMed
  71. Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
    2019 | PubMed
  72. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
    2019 | PubMed
  73. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
    2017 | PubMed
  74. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    2017 | PubMed
  75. Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
    2015 | PubMed
  76. The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
    2015 | PubMed
  77. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  78. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    2012 | PubMed
  79. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  80. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    2007 | PubMed
  81. Anti-angiogenic strategies in gastrointestinal malignancies.
    2005 | PubMed
  82. Couples therapy at end of life.
    2003 | PubMed
  83. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
    2000 | PubMed
  84. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  85. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    2017 | PubMed
  86. Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.
    2013 | PubMed
  87. Is there currently an established role for the use of predictive or prognostic molecular markers in the management of colorectal cancer? A point/counterpoint.
    2012 | PubMed
  88. p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
    2009 | PubMed
  89. Palliative care for patients with advanced pancreatic and biliary cancers.
    2007 | PubMed
  90. Liver-directed therapies in colorectal cancer.
    2005 | PubMed
  91. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis.
    2002 | PubMed
  92. Digitoxin metabolism by rat liver microsomes.
    1975 | PubMed
  93. Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data.
    2025 | PubMed
  94. Spatial Transcriptomics Reveals Location-Specific Tumor Cell Subtypes and Signaling within Multifocal Small Intestinal Neuroendocrine Tumors.
    2026 | PubMed
  95. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    2025 | PubMed
  96. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer?
    2024 | PubMed
  97. A Machine Learning Approach to Predict Postoperative Pancreatic Fistula After Pancreaticoduodenectomy Using Only Preoperatively Known Data.
    2023 | PubMed
  98. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    2023 | PubMed
  99. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    2021 | PubMed
  100. Contemporary Management of Hepatic Cyst Disease: Techniques and Outcomes at a Tertiary Hepatobiliary Center.
    2020 | PubMed
  101. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  102. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  103. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    2016 | PubMed
  104. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.
    2014 | PubMed
  105. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
    2012 | PubMed
  106. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  107. Palliative care for patients with advanced pancreatic and biliary cancers.
    2007 | PubMed
  108. Management of hepatocellular carcinoma.
    2000 | PubMed
  109. Immunotherapy for Metastatic Pancreatic Neuroendocrine Tumors with High Mutational Burden and Mismatch Repair Alterations Following Treatment with Alkylating Chemotherapy.
    2025 | PubMed
  110. Flip Angle Optimization for Hepatobiliary Phase MRI at 0.55 T in Patients With Metastatic Neuroendocrine Tumors: A Prospective Study.
    2025 | PubMed
  111. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
    2024 | PubMed
  112. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
    2023 | PubMed
  113. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
    2023 | PubMed
  114. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
    2021 | PubMed
  115. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    2021 | PubMed
  116. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of
    2020 | PubMed
  117. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
    2020 | PubMed
  118. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  119. A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
    2018 | PubMed
  120. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
    2017 | PubMed
  121. Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
    2016 | PubMed
  122. Transcatheter pulmonic valve replacement in carcinoid heart disease.
    2015 | PubMed
  123. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
    2014 | PubMed
  124. The evolving landscape of neuroendocrine tumors.
    2013 | PubMed
  125. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
    2010 | PubMed
  126. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
    2008 | PubMed
  127. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
    2006 | PubMed
  128. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    2005 | PubMed
  129. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
    2003 | PubMed
  130. STAT3 regulates inflammatory cytokine production downstream of TNFR1 by inducing expression of TNFAIP3/A20.
    2022 | PubMed
  131. RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.
    2019 | PubMed
  132. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
    2016 | PubMed
  133. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  134. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
    2011 | PubMed
  135. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  136. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481).
    2006 | PubMed
  137. Aggressive surgery for metastatic liver neuroendocrine tumors.
    2003 | PubMed
  138. Quantitative fractionation of alkaline phosphatase isoenzymes according to their thermostability.
    1976 | PubMed
  139. BIO26-035: Validation of an Electronic Health Record Phenotype for Advanced Solid Cancer Across Five University of California Health Systems.
    2026 | PubMed
  140. True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm.
    2026 | PubMed
  141. Graft choice in pancreatectomy with vascular resection: equivalent safety in selected patients.
    2024 | PubMed
  142. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2024 | PubMed
  143. Residual Tumor Volume, Not Percent Cytoreduction, Matters for Surgery of Neuroendocrine Liver Metastasis.
    2023 | PubMed
  144. Hand-Assisted Versus Pure Minimally-Invasive Distal Pancreatectomy: Is There a Downside to Lending a Hand?
    2022 | PubMed
  145. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
    2021 | PubMed
  146. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    2020 | PubMed
  147. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  148. Challenges Staging Neuroendocrine Tumors of the Pancreas, Jejunum and Ileum, and Appendix.
    2017 | PubMed
  149. Solid pseudopapillary neoplasm of the pancreas head in a pregnant woman: safe pancreaticoduodenectomy postpartum.
    2015 | PubMed
  150. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
    2013 | PubMed
  151. Unique patterns of metastases in common and rare types of malignancy.
    2011 | PubMed
  152. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
    2008 | PubMed
  153. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.
    2006 | PubMed
  154. Potent and effective prolongation by anti-LFA-1 monoclonal antibody monotherapy of non-primarily vascularized heart allograft survival in mice without T cell depletion.
    1993 | PubMed
  155. Pancreatic neuroendocrine tumors and MUTYH pathogenic variants: a multinational study.
    2025 | PubMed
  156. Factors associated with grade progression in pancreatic neuroendocrine tumors.
    2025 | PubMed
  157. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
    2024 | PubMed
  158. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
    2023 | PubMed
  159. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
    2022 | PubMed
  160. Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
    2021 | PubMed
  161. Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
    2021 | PubMed
  162. Reply to S. Boutayeb et al.
    2020 | PubMed
  163. Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
    2019 | PubMed
  164. Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
    2019 | PubMed
  165. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
    2018 | PubMed
  166. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
    2017 | PubMed
  167. Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
    2016 | PubMed
  168. Is more not better?: combination therapies in colorectal cancer treatment.
    2015 | PubMed
  169. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
    2014 | PubMed
  170. Neuroendocrine tumors.
    2012 | PubMed
  171. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
    2010 | PubMed
  172. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    2007 | PubMed
  173. When does the presence of the target predict response to the targeted agent?
    2005 | PubMed
  174. Angiogenesis in colorectal cancer: therapeutic implications and future directions.
    2004 | PubMed
  175. Molecular mechanisms underlying the development of hepatocellular carcinoma.
    2001 | PubMed
  176. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  177. Discontinuities in soil strength contribute to destabilization of nutrient-enriched creeks.
    2018 | PubMed
  178. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    2014 | PubMed
  179. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  180. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  181. Prognostic importance of superior diaphragmatic adenopathy at computed tomography in patients with resectable hepatic metastases from colorectal carcinoma.
    2008 | PubMed
  182. Hypoxia-induced radioresistance is independent of hypoxia-inducible factor-1A in vitro.
    2005 | PubMed
  183. Isolation, sequencing, and expression of a cDNA for the HXM-A form of xenobiotic/medium-chain fatty acid:CoA ligase from human liver mitochondria.
    2003 | PubMed
  184. Analyses of rumen fluid from "sudden death", lactic acidotic and healthy cattle fed high concentrate ration.
    1975 | PubMed
  185. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing.
    2026 | PubMed
  186. Video-based assessment identifies intraoperative predictors of clinically relevant POPF following minimally invasive distal pancreatectomy.
    2026 | PubMed
  187. Minimally Invasive Versus Open Resection for Solid Pseudopapillary Tumors of the Pancreas: A Propensity Score-Matched Analysis.
    2025 | PubMed
  188. Enucleation of Neuroendocrine Liver Metastases.
    2024 | PubMed
  189. Robotic-assisted endoluminal gastric leiomyoma resection: a novel surgical technique for benign gastroesophageal junction tumors.
    2024 | PubMed
  190. Laparoscopic Gastrectomy for Gastric Cancer.
    2023 | PubMed
  191. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis.
    2022 | PubMed
  192. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
    2021 | PubMed
  193. Ampullary stenosis and choledocholithiasis post Roux-En-Y gastric bypass: challenges of biliary access and intervention.
    2020 | PubMed
  194. Pancreatic Adenocarcinoma, Version 1.2019.
    2019 | PubMed
  195. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    2017 | PubMed
  196. Bone metastases and skeletal-related events from neuroendocrine tumors.
    2014 | PubMed
  197. Can CT features differentiate between inferior vena cava leiomyosarcomas and primary retroperitoneal masses?
    2013 | PubMed
  198. Arterial embolization for the management of gastrointestinal hemorrhage from metastatic renal cell carcinoma.
    2010 | PubMed
  199. Introduction.
    2007 | PubMed
  200. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells.
    2001 | PubMed
  201. ACR Appropriateness Criteria® Staging and Follow-Up of Pancreatic Neuroendocrine Tumors.
    2026 | PubMed
  202. Symptom Management for Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    2025 | PubMed
  203. Withdrawal pain following patients discontinuing Trk inhibitors.
    2024 | PubMed
  204. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.
    2023 | PubMed
  205. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
    2023 | PubMed
  206. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
    2022 | PubMed
  207. The Immunotherapy Landscape in Adrenocortical Cancer.
    2021 | PubMed
  208. New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
    2020 | PubMed
  209. Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
    2020 | PubMed
  210. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  211. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
    2019 | PubMed
  212. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
    2017 | PubMed
  213. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
    2016 | PubMed
  214. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    2015 | PubMed
  215. Bone metastases and skeletal-related events from neuroendocrine tumors.
    2014 | PubMed
  216. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    2013 | PubMed
  217. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
    2011 | PubMed
  218. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
    2008 | PubMed
  219. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
    2007 | PubMed
  220. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
    2005 | PubMed
  221. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    2003 | PubMed
  222. Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.
    1997 | PubMed
  223. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
    2019 | PubMed
  224. Reply to L. Casadaban et al.
    2017 | PubMed
  225. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.
    2013 | PubMed
  226. Complete and safe resection of challenging retroperitoneal tumors: anticipation of multi-organ and major vascular resection and use of adjunct procedures.
    2011 | PubMed
  227. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    2009 | PubMed
  228. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2.
    2007 | PubMed
  229. Palliative techniques for hepatic cancer.
    2004 | PubMed
  230. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.
    2002 | PubMed
  231. How to implement DPYD genotyping into practice.
    2026 | PubMed
  232. Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance).
    2025 | PubMed
  233. ASO Visual Abstract: True Incidence of Appendiceal Neoplasms in Patients Presenting with Complicated Appendicitis: A Call for a Revised Management Algorithm.
    2026 | PubMed
  234. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer.
    2025 | PubMed
  235. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    2024 | PubMed
  236. ASO Visual Abstract: National Practice Patterns in Malignant Peritoneal Mesothelioma-Updates in Management and Survival.
    2023 | PubMed
  237. Hypertension Requiring Medication Use: a Silent Predictor of Poor Outcomes After Pancreaticoduodenectomy.
    2023 | PubMed
  238. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
    2021 | PubMed
  239. Hybrid Low-Grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma of the Pancreas.
    2020 | PubMed
  240. Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
    2019 | PubMed
  241. Outcomes of arterial bypass preceding resection of retroperitoneal masses involving major vessels.
    2018 | PubMed
  242. Finding the Common Thread in Rare Diseases.
    2016 | PubMed
  243. Time to put another surgical dogma to sleep?
    2014 | PubMed
  244. Pseudomyxoma peritonei: more questions than answers.
    2012 | PubMed
  245. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer.
    2009 | PubMed
  246. Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
    2007 | PubMed
  247. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy.
    1996 | PubMed
  248. Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202).
    2025 | PubMed
  249. Metastatic insulinoma-outcomes in the current era.
    2025 | PubMed
  250. Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2024 | PubMed
  251. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.
    2023 | PubMed
  252. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
    2023 | PubMed
  253. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
    2021 | PubMed
  254. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2021 | PubMed
  255. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
    2020 | PubMed
  256. A Rare Case of Carcinoid Constrictive Pericarditis.
    2020 | PubMed
  257. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
    2019 | PubMed
  258. Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
    2018 | PubMed
  259. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
    2017 | PubMed
  260. A phase II study of axitinib in advanced neuroendocrine tumors.
    2016 | PubMed
  261. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
    2015 | PubMed
  262. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
    2014 | PubMed
  263. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
    2012 | PubMed
  264. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  265. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
    2008 | PubMed
  266. Pancreatoblastoma in an adult: case report and review of the literature.
    2006 | PubMed
  267. Update on clinical trials targeting vascular endothelial growth factor in cancer.
    2004 | PubMed
  268. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.
    2003 | PubMed
  269. Synchronous Versus Metachronous Colorectal Liver Metastasis Yields Similar Survival in Modern Era.
    2020 | PubMed
  270. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  271. Unexpected insights for anti-EGFR cancer therapy.
    2015 | PubMed
  272. Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
    2013 | PubMed
  273. Pancreatic adenocarcinoma.
    2010 | PubMed
  274. Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
    2008 | PubMed
  275. Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology.
    2005 | PubMed
  276. beta-Catenin regulates vascular endothelial growth factor expression in colon cancer.
    2003 | PubMed
  277. Activity and longevity of insect growth regulators against mosquitoes.
    1975 | PubMed
  278. Sex differences in efficacy and toxicity of first-line treatment of metastatic colorectal cancer: An analysis of 18,041 patients in the ARCAD CRC database.
    2026 | PubMed
  279. ASO Visual Abstract: Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival.
    2026 | PubMed
  280. Minimally Invasive Distal Pancreatectomy as the Standard of Care in the US: Are We There Yet?
    2025 | PubMed
  281. ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.
    2024 | PubMed
  282. National practice patterns in the use of endoscopic ultrasound biopsy for resectable Pancreatic Neuroendocrine Tumors: Insights into the role of DOTATATE PET/CT in diagnosis.
    2024 | PubMed
  283. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.
    2023 | PubMed
  284. Minimally Invasive Distal Pancreatectomy Techniques: A Contemporary Analysis Exploring Trends, Similarities, and Differences to Open Surgery.
    2022 | PubMed
  285. Burden of Ionizing Radiation in the Diagnosis and Management of Necrotizing Pancreatitis.
    2021 | PubMed
  286. Awareness of a mesenteric mass as a common manifestation of ileal neuroendocrine tumor.
    2020 | PubMed
  287. Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
    2019 | PubMed
  288. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    2017 | PubMed
  289. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
    2015 | PubMed
  290. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver.
    2013 | PubMed
  291. Pancreatic adenocarcinoma.
    2010 | PubMed
  292. Compound muscle action potentials and spontaneous electromyography can be used to identify and protect the femoral nerve during resection of large retroperitoneal tumors.
    2008 | PubMed
  293. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling.
    2005 | PubMed
  294. Patterns of Progression After Peptide Receptor Radiopharmaceutical Therapy.
    2026 | PubMed
  295. Consensus guideline for the management of peritoneal metastases from neuroendocrine neoplasms.
    2025 | PubMed
  296. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53.
    2024 | PubMed
  297. The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
    2024 | PubMed
  298. Preclinical Models of Adrenocortical Cancer.
    2023 | PubMed
  299. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
    2022 | PubMed
  300. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    2021 | PubMed
  301. Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
    2021 | PubMed
  302. Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
    2020 | PubMed
  303. Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
    2019 | PubMed
  304. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  305. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
    2018 | PubMed
  306. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
    2017 | PubMed
  307. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
    2015 | PubMed
  308. Neuroendocrine tumors, version 1.2015.
    2015 | PubMed
  309. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    2013 | PubMed
  310. Systemic therapy for advanced carcinoid tumors: where do we go from here?
    2012 | PubMed
  311. Glycemic control in patients with insulinoma treated with everolimus.
    2009 | PubMed
  312. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
    2007 | PubMed
  313. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
    2005 | PubMed
  314. Maximizing the potential of bevacizumab in cancer treatment.
    2004 | PubMed
  315. Hepatocellular carcinoma.
    2000 | PubMed
  316. Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
    2019 | PubMed
  317. Sampling strategies to capture single-cell heterogeneity.
    2017 | PubMed
  318. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
    2013 | PubMed
  319. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
    2012 | PubMed
  320. The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
    2010 | PubMed
  321. Introduction.
    2007 | PubMed
  322. Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
    2005 | PubMed
  323. Thorotrast-induced liver neoplasia: a collective review.
    2002 | PubMed
  324. Action of propranolol on mitochondrial functions--effects on energized ion fluxes in the presence of valinomycin.
    1975 | PubMed
  325. Shifts in the human gut microbiome during cancer chemotherapy are diet-dependent.
    2025 | PubMed
  326. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival.
    2026 | PubMed
  327. Robotic-assisted trans-mesocolic side-to-side duodenojejunostomy for palliative management of malignant distal duodenal obstruction.
    2025 | PubMed
  328. Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment.
    2024 | PubMed
  329. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
    2024 | PubMed
  330. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    2023 | PubMed
  331. Optimal Staging for Gastric Cancer Starts With High-Resolution Computed Tomography.
    2021 | PubMed
  332. Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
    2021 | PubMed
  333. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  334. Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
    2019 | PubMed
  335. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
    2017 | PubMed
  336. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    2014 | PubMed
  337. Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
    2012 | PubMed
  338. Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
    2010 | PubMed
  339. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
    2007 | PubMed
  340. Mammalian Scratch: a neural-specific Snail family transcriptional repressor.
    2001 | PubMed
  341. Precision imaging and evolving therapies in paragangliomas and pheochromocytomas: from molecular diagnostics to imaging-guided management.
    2026 | PubMed
  342. Appropriate use of tissue sampling and somatostatin receptor PET imaging in the diagnosis of pancreatic neuroendocrine tumors: results of an International Delphi Consensus.
    2025 | PubMed
  343. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
    2024 | PubMed
  344. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
    2023 | PubMed
  345. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
    2023 | PubMed
  346. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
    2022 | PubMed
  347. Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
    2021 | PubMed
  348. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
    2020 | PubMed
  349. A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
    2020 | PubMed
  350. Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
    2019 | PubMed
  351. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
    2018 | PubMed
  352. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
    2017 | PubMed
  353. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
    2016 | PubMed
  354. A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
    2015 | PubMed
  355. Neuroendocrine tumors of unknown primary: is the primary site really not known?
    2014 | PubMed
  356. Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.
    2013 | PubMed
  357. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
    2011 | PubMed
  358. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    2008 | PubMed
  359. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
    2007 | PubMed
  360. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    2005 | PubMed
  361. Immune enhancement of skin carcinogenesis by CD4+ T cells.
    2003 | PubMed
  362. Metastatic colorectal adenocarcinoma tumor purity assessment from whole exome sequencing data.
    2023 | PubMed
  363. High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
    2019 | PubMed
  364. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    2016 | PubMed
  365. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival.
    2013 | PubMed
  366. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
    2011 | PubMed
  367. Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers.
    2008 | PubMed
  368. Pancreatoblastoma in an adult: case report and review of the literature.
    2006 | PubMed
  369. Characterization of triacsin C inhibition of short-, medium-, and long-chain fatty acid: CoA ligases of human liver.
    2004 | PubMed
  370. Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells.
    2002 | PubMed
  371. BIO26-035: MTAP Deficiency in Thoracic Oncology: Bridging Genomic Loss, Survival Deficits, and Immunosuppressive Microenvironments.
    2026 | PubMed
  372. Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    2025 | PubMed